DXCM vs. ONC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DXCM and ONC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
DXCM is a standard domestic listing, while ONC trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | DXCM | ONC |
|---|---|---|
| Company Name | DexCom, Inc. | BeOne Medicines AG |
| Country | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 26.31 billion USD | 37.96 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | April 14, 2005 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of DXCM and ONC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DXCM | ONC |
|---|---|---|
| 5-Day Price Return | -0.31% | -0.90% |
| 13-Week Price Return | -22.91% | 32.50% |
| 26-Week Price Return | -6.71% | 41.02% |
| 52-Week Price Return | 0.00% | 20.61% |
| Month-to-Date Return | -10.68% | 10.40% |
| Year-to-Date Return | -13.48% | 90.60% |
| 10-Day Avg. Volume | 8.55M | 4.56M |
| 3-Month Avg. Volume | 4.20M | 4.05M |
| 3-Month Volatility | 42.00% | 51.09% |
| Beta | 1.41 | 0.78 |
Profitability
Return on Equity (TTM)
DXCM
25.62%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
In the upper quartile for the Health Care Equipment & Supplies industry, DXCM’s Return on Equity of 25.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ONC
-6.58%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
ONC has a negative Return on Equity of -6.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
DXCM
13.29%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
DXCM’s Net Profit Margin of 13.29% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
ONC
-5.04%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
ONC has a negative Net Profit Margin of -5.04%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
DXCM
15.98%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
DXCM’s Operating Profit Margin of 15.98% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
ONC
-2.03%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
ONC has a negative Operating Profit Margin of -2.03%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | DXCM | ONC |
|---|---|---|
| Return on Equity (TTM) | 25.62% | -6.58% |
| Return on Assets (TTM) | 8.49% | -3.87% |
| Net Profit Margin (TTM) | 13.29% | -5.04% |
| Operating Profit Margin (TTM) | 15.98% | -2.03% |
| Gross Profit Margin (TTM) | 60.01% | 85.37% |
Financial Strength
Current Ratio (MRQ)
DXCM
1.52
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
DXCM’s Current Ratio of 1.52 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
ONC
1.94
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
ONC’s Current Ratio of 1.94 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DXCM
0.97
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
DXCM’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.97. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
ONC
0.27
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
ONC’s Debt-to-Equity Ratio of 0.27 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DXCM
978.00
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
With an Interest Coverage Ratio of 978.00, DXCM demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.
ONC
-132.16
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
ONC has a negative Interest Coverage Ratio of -132.16. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | DXCM | ONC |
|---|---|---|
| Current Ratio (MRQ) | 1.52 | 1.94 |
| Quick Ratio (MRQ) | 1.32 | 1.65 |
| Debt-to-Equity Ratio (MRQ) | 0.97 | 0.27 |
| Interest Coverage Ratio (TTM) | 978.00 | -132.16 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
DXCM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ONC
0.17%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC’s Dividend Yield of 0.17% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio (TTM)
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
DXCM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ONC
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | DXCM | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.17% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DXCM
46.09
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
DXCM’s P/E Ratio of 46.09 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ONC
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for ONC is currently unavailable.
Price-to-Sales Ratio (TTM)
DXCM
6.12
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
DXCM’s P/S Ratio of 6.12 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
ONC
9.25
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
ONC’s P/S Ratio of 9.25 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
DXCM
13.30
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
At 13.30, DXCM’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
ONC
8.16
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
ONC’s P/B Ratio of 8.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | DXCM | ONC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 46.09 | -- |
| Price-to-Sales Ratio (TTM) | 6.12 | 9.25 |
| Price-to-Book Ratio (MRQ) | 13.30 | 8.16 |
| Price-to-Free Cash Flow Ratio (TTM) | 46.14 | 156.50 |